55th Annual Meeting of the European Association for the Study of Diabetes (EASD 2019)

Upfront vildagliptin-metformin combo improves glycaemic durability in newly diagnosed T2D

Roshini Claire Anthony, 20191031140102

Upfront combination therapy with metformin and the DPP-4* inhibitor vildagliptin may improve glycaemic durability in patients newly diagnosed with type 2 diabetes (T2D) compared with sequential therapy with metformin monotherapy followed by vildagliptin, results from the VERIFY** trial showed.

Tirzepatide shows benefits for T2D

Audrey Abella, 20191025100000

The novel dual GIP* and GLP-1** receptor agonist tirzepatide demonstrated clinically meaningful improvements in glycaemic control and weight loss in patients with type 2 diabetes (T2D), according to data presented at EASD 2019.

Sotagliflozin holds promise for T1D

Audrey Abella, 20191023094117

The addition of the dual SGLT*1 and SGLT2 inhibitor sotagliflozin to insulin led to improvements in glycaemic control, body weight, and systolic blood pressure (SBP) in overweight/obese individuals with type 1 diabetes (T1D), according to a post hoc analysis presented at EASD 2019.

Semaglutide bests canagliflozin for HbA1c, weight reductions in T2D

Roshini Claire Anthony, 20191019070101

In patients with type 2 diabetes (T2D) inadequately controlled on metformin, semaglutide may have a greater impact than canagliflozin in reducing HbA_1c levels and bodyweight, according to the phase IIIb SUSTAIN 8* trial presented at EASD 2019.

CAROLINA: CV safety of linagliptin noninferior to glimepiride in patients with early T2D

Roshini Claire Anthony, 20191004140202

The incidence of cardiovascular (CV) death, nonfatal myocardial infarction (MI), or nonfatal stroke (three-point MACE*) was comparable in individuals with early stage type 2 diabetes (T2D) who received the DPP-4** inhibitor linagliptin or the sulfonylurea glimepiride in addition to usual care, according to results of the CAROLINA*** trial.

Gestational diabetes risk elevated following ART

Roshini Claire Anthony, 20190930140302

Women who conceive singleton pregnancies following assisted reproductive technology (ART) may have a higher risk of developing gestational diabetes than those who conceive spontaneously, according to results of a systematic review and meta-analysis presented at EASD 2019.